JP2002531505A - 糖脂質蓄積症を治療する薬物製造のためのデオキシノジリマイシンの長鎖ｎ−アルキル誘導体の使用 - Google Patents
糖脂質蓄積症を治療する薬物製造のためのデオキシノジリマイシンの長鎖ｎ−アルキル誘導体の使用Info
- Publication number
- JP2002531505A JP2002531505A JP2000586335A JP2000586335A JP2002531505A JP 2002531505 A JP2002531505 A JP 2002531505A JP 2000586335 A JP2000586335 A JP 2000586335A JP 2000586335 A JP2000586335 A JP 2000586335A JP 2002531505 A JP2002531505 A JP 2002531505A
- Authority
- JP
- Japan
- Prior art keywords
- dnj
- nonyl
- chain
- deoxynojirimycin
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 title claims abstract description 30
- 229930186217 Glycolipid Natural products 0.000 title claims abstract description 30
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 title claims abstract description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 24
- 201000010099 disease Diseases 0.000 title claims description 22
- 239000003814 drug Substances 0.000 title description 3
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 30
- 208000015872 Gaucher disease Diseases 0.000 claims abstract description 13
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 13
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 5
- FTSCEGKYKXESFF-LXTVHRRPSA-N N-nonyldeoxynojirimycin Chemical compound CCCCCCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO FTSCEGKYKXESFF-LXTVHRRPSA-N 0.000 claims description 33
- 239000003085 diluting agent Substances 0.000 claims description 8
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract description 4
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract description 3
- UQRORFVVSGFNRO-UTINFBMNSA-N miglustat Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 28
- 150000001875 compounds Chemical class 0.000 description 25
- 229960001512 miglustat Drugs 0.000 description 18
- 230000000694 effects Effects 0.000 description 17
- 230000005764 inhibitory process Effects 0.000 description 17
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 16
- 230000035508 accumulation Effects 0.000 description 13
- 238000009825 accumulation Methods 0.000 description 13
- 210000004556 brain Anatomy 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 9
- 102000044956 Ceramide glucosyltransferases Human genes 0.000 description 9
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 9
- 229940106189 ceramide Drugs 0.000 description 9
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 9
- 108091000114 ceramide glucosyltransferase Proteins 0.000 description 9
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- -1 cis-11-hexadecenyl Chemical group 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- GYHFUZHODSMOHU-UHFFFAOYSA-N nonanal Chemical compound CCCCCCCCC=O GYHFUZHODSMOHU-UHFFFAOYSA-N 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 108010017544 Glucosylceramidase Proteins 0.000 description 5
- 102000004547 Glucosylceramidase Human genes 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 108010028144 alpha-Glucosidases Proteins 0.000 description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 4
- KSMVZQYAVGTKIV-UHFFFAOYSA-N decanal Chemical compound CCCCCCCCCC=O KSMVZQYAVGTKIV-UHFFFAOYSA-N 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 230000036962 time dependent Effects 0.000 description 4
- 102000004366 Glucosidases Human genes 0.000 description 3
- 108010056771 Glucosidases Proteins 0.000 description 3
- 108700023372 Glycosyltransferases Proteins 0.000 description 3
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 150000002305 glucosylceramides Chemical class 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000003305 oral gavage Methods 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- 102000051366 Glycosyltransferases Human genes 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 102100025315 Mannosyl-oligosaccharide glucosidase Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- HSCJRCZFDFQWRP-JZMIEXBBSA-N UDP-alpha-D-glucose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OP(O)(=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-JZMIEXBBSA-N 0.000 description 2
- HSCJRCZFDFQWRP-UHFFFAOYSA-N Uridindiphosphoglukose Natural products OC1C(O)C(O)C(CO)OC1OP(O)(=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(NC(=O)C=C2)=O)O1 HSCJRCZFDFQWRP-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 2
- 238000000326 densiometry Methods 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 108010050669 glucosidase I Proteins 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 150000003839 salts Chemical group 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- UQRORFVVSGFNRO-XFWSIPNHSA-N (2r,3s,4r,5s)-1-butyl-2-(hydroxymethyl)piperidine-3,4,5-triol Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@@H](O)[C@H]1CO UQRORFVVSGFNRO-XFWSIPNHSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 201000008892 GM1 Gangliosidosis Diseases 0.000 description 1
- 229940127551 Glucosyl Transferase Inhibitors Drugs 0.000 description 1
- 102000000340 Glucosyltransferases Human genes 0.000 description 1
- 108010055629 Glucosyltransferases Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 238000007126 N-alkylation reaction Methods 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 102000016679 alpha-Glucosidases Human genes 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000008687 biosynthesis inhibition Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 229940049197 cerezyme Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 102000045442 glycosyltransferase activity proteins Human genes 0.000 description 1
- 108700014210 glycosyltransferase activity proteins Proteins 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 108010039650 imiglucerase Proteins 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000003868 tissue accumulation Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11168398P | 1998-12-10 | 1998-12-10 | |
| US60/111,683 | 1998-12-10 | ||
| PCT/US1999/027918 WO2000033843A1 (en) | 1998-12-10 | 1999-12-08 | Use of long-chain n-alkyl derivatives of deoxynojirimycin for the manufacture of a medicament for the treatment of glycolipid storage diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002531505A true JP2002531505A (ja) | 2002-09-24 |
| JP2002531505A5 JP2002531505A5 (https=) | 2007-01-11 |
Family
ID=22339901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000586335A Pending JP2002531505A (ja) | 1998-12-10 | 1999-12-08 | 糖脂質蓄積症を治療する薬物製造のためのデオキシノジリマイシンの長鎖ｎ−アルキル誘導体の使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6610703B1 (https=) |
| EP (1) | EP1137416B1 (https=) |
| JP (1) | JP2002531505A (https=) |
| AT (1) | ATE226821T1 (https=) |
| AU (1) | AU2347500A (https=) |
| CA (1) | CA2352544C (https=) |
| DE (1) | DE69903750T2 (https=) |
| DK (1) | DK1137416T3 (https=) |
| ES (1) | ES2190674T3 (https=) |
| PT (1) | PT1137416E (https=) |
| WO (1) | WO2000033843A1 (https=) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6465488B1 (en) | 1997-12-11 | 2002-10-15 | Chancellor, Masters & Scholars Of The University Of Oxford | Inhibition of glycolipid biosynthesis |
| US6274597B1 (en) | 1998-06-01 | 2001-08-14 | Mount Sinai School Of Medicine Of New York University | Method of enhancing lysosomal α-Galactosidase A |
| GB9909064D0 (en) * | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
| GB9909066D0 (en) * | 1999-04-20 | 1999-06-16 | Oxford Glycosciences Uk Ltd | Therapies |
| GB0100889D0 (en) | 2001-01-12 | 2001-02-21 | Oxford Glycosciences Uk Ltd | Compounds |
| WO2001097829A2 (en) * | 2000-06-19 | 2001-12-27 | Genzyme Corporation | Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases |
| AU2003248960B2 (en) | 2002-07-17 | 2009-06-25 | Idorsia Pharmaceuticals Ltd | Piperidinetriol derivatives as inhibitors of glycosylceramidsynthase |
| AU2003246942B2 (en) | 2002-07-17 | 2009-06-25 | Idorsia Pharmaceuticals Ltd | Piperidinetriol derivatives as inhibitors of glycosylceramide synthase |
| GB0313678D0 (en) | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compounds |
| GB0313677D0 (en) | 2003-06-13 | 2003-07-16 | Oxford Glycosciences Uk Ltd | Novel compound |
| US8003617B2 (en) * | 2004-11-10 | 2011-08-23 | Genzyme Corporation | Methods of treating diabetes mellitus |
| PL2032134T3 (pl) * | 2006-05-09 | 2015-11-30 | Genzyme Corp | Sposoby leczenia stłuszczeniowej choroby wątroby obejmujące hamowanie syntezy glikosfingolipidów |
| GB0614947D0 (en) * | 2006-07-27 | 2006-09-06 | Isis Innovation | Epitope reduction therapy |
| US8097728B2 (en) * | 2007-04-30 | 2012-01-17 | Philadelphia Health & Education Corporation | Iminosugar compounds with antiflavirus activity |
| EP2594562B1 (en) | 2007-05-31 | 2016-07-20 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitors |
| ES2660690T3 (es) * | 2007-10-05 | 2018-03-23 | Genzyme Corporation | Método para tratar poliquistosis renales con derivados de ceramida |
| CA2731685A1 (en) * | 2008-07-28 | 2010-02-04 | Genzyme Corporation | Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease |
| EP3078373A1 (en) | 2008-10-03 | 2016-10-12 | Genzyme Corporation | 2-acylaminopropanol-type glucosylceramide synthase inhibitor |
| CA3040973A1 (en) | 2008-12-16 | 2010-07-01 | Genzyme Corporation | Oligosaccharide-protein conjugates |
| CA2753195C (en) | 2009-02-23 | 2015-06-02 | United Therapeutics Corporation | Iminosugars and methods of treating viral diseases |
| ES2562635T3 (es) * | 2009-02-24 | 2016-03-07 | United Therapeutics Corporation | Iminoazúcares y métodos de tratamiento de infecciones producidas por arenavirus |
| CA2793276A1 (en) * | 2009-03-27 | 2010-09-30 | Zacharon Pharmaceuticals, Inc. | Ganglioside biosynthesis modulators |
| CN102639133B (zh) | 2009-06-12 | 2015-03-11 | 联合治疗公司 | 亚氨基糖和治疗布尼亚病毒性疾病以及披膜病毒性疾病的方法 |
| WO2011028779A1 (en) * | 2009-09-04 | 2011-03-10 | United Therapeutics Corporation | Iminosugars and methods of treating filoviral diseases |
| CN102625801B (zh) * | 2009-09-04 | 2015-09-09 | 联合治疗公司 | 治疗痘病毒感染的方法 |
| KR101497194B1 (ko) * | 2009-09-04 | 2015-02-27 | 유나이티드 세러퓨틱스 코오포레이션 | 오르토믹소바이러스 감염의 치료 방법 |
| WO2011066352A1 (en) | 2009-11-27 | 2011-06-03 | Genzyme Corporation | An amorphous and a crystalline form of genz 112638 hemitartrat as inhibitor of glucosylceramide synthase |
| WO2013059119A1 (en) | 2011-10-17 | 2013-04-25 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| WO2014017915A2 (en) | 2012-07-27 | 2014-01-30 | Universiteit Utrecht Holding B.V. | Urea and guanidinium derivatives of iminosugars |
| CN106102464A (zh) * | 2013-05-02 | 2016-11-09 | 牛津大学之校长及学者 | 采用亚氨基糖的糖脂抑制 |
| ES2856898T3 (es) | 2015-02-02 | 2021-09-28 | Univ Michigan Regents | Inhibidores de glucosilceramida sintasa y métodos terapéuticos que usan los mismos |
| EP3318277A1 (en) | 2016-11-04 | 2018-05-09 | Institut du Cerveau et de la Moelle Epiniere-ICM | Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases |
| WO2020193746A1 (en) | 2019-03-28 | 2020-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival of patients suffering from melanoma |
| WO2021081141A1 (en) | 2019-10-23 | 2021-04-29 | The Regents Of The University Of Michigan | Glucosylceramide synthase inhibitors and therapeutic methods using the same |
| JP7725076B2 (ja) | 2020-04-28 | 2025-08-19 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン | グルコシルセラミド合成酵素のピリジン阻害剤及びそれらを使用する治療方法 |
| KR102826412B1 (ko) * | 2022-11-01 | 2025-06-26 | 차의과학대학교 산학협력단 | N-노닐데옥시노지리마이신을 포함하는 피부 가려움증의 억제, 경감, 개선, 또는 치료를 위한 조성물 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61200967A (ja) * | 1985-02-28 | 1986-09-05 | バイエル・アクチエンゲゼルシヤフト | ３，４，５‐トリヒドロキシピペリジン類、その製法および用途 |
| WO1998002161A1 (en) * | 1996-07-15 | 1998-01-22 | Universiteit Van Amsterdam | Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5030638A (en) | 1990-02-26 | 1991-07-09 | G. D. Searle & Co. | Method of antiviral enhancement |
| US6291657B1 (en) | 1993-05-13 | 2001-09-18 | Monsanto Company | Deoxygalactonojirimycin derivatives |
| US5399567A (en) | 1993-05-13 | 1995-03-21 | Monsanto Company | Method of treating cholera |
| US5798366A (en) | 1993-05-13 | 1998-08-25 | Monsanto Company | Method for treatment of CNS-involved lysosomal storage diseases |
| CA2252238A1 (en) | 1997-10-31 | 1999-04-30 | Sun Microsystems, Inc. | Method and apparatus for sharing a time quantum |
-
1999
- 1999-12-02 US US09/453,754 patent/US6610703B1/en not_active Expired - Fee Related
- 1999-12-08 AT AT99967135T patent/ATE226821T1/de not_active IP Right Cessation
- 1999-12-08 CA CA002352544A patent/CA2352544C/en not_active Expired - Fee Related
- 1999-12-08 DE DE69903750T patent/DE69903750T2/de not_active Expired - Fee Related
- 1999-12-08 ES ES99967135T patent/ES2190674T3/es not_active Expired - Lifetime
- 1999-12-08 WO PCT/US1999/027918 patent/WO2000033843A1/en not_active Ceased
- 1999-12-08 EP EP99967135A patent/EP1137416B1/en not_active Expired - Lifetime
- 1999-12-08 JP JP2000586335A patent/JP2002531505A/ja active Pending
- 1999-12-08 PT PT99967135T patent/PT1137416E/pt unknown
- 1999-12-08 AU AU23475/00A patent/AU2347500A/en not_active Abandoned
- 1999-12-08 DK DK99967135T patent/DK1137416T3/da active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS61200967A (ja) * | 1985-02-28 | 1986-09-05 | バイエル・アクチエンゲゼルシヤフト | ３，４，５‐トリヒドロキシピペリジン類、その製法および用途 |
| WO1998002161A1 (en) * | 1996-07-15 | 1998-01-22 | Universiteit Van Amsterdam | Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| ES2190674T3 (es) | 2003-08-01 |
| DE69903750D1 (de) | 2002-12-05 |
| WO2000033843A1 (en) | 2000-06-15 |
| CA2352544C (en) | 2007-11-13 |
| DK1137416T3 (da) | 2003-03-03 |
| US6610703B1 (en) | 2003-08-26 |
| ATE226821T1 (de) | 2002-11-15 |
| DE69903750T2 (de) | 2003-06-12 |
| EP1137416A1 (en) | 2001-10-04 |
| CA2352544A1 (en) | 2000-06-15 |
| AU2347500A (en) | 2000-06-26 |
| EP1137416B1 (en) | 2002-10-30 |
| PT1137416E (pt) | 2003-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002531505A (ja) | 糖脂質蓄積症を治療する薬物製造のためのデオキシノジリマイシンの長鎖ｎ−アルキル誘導体の使用 | |
| EP1196190B1 (en) | Use of long-chain n-alkyl derivatives of deoxynojirimycin and a glucocerebrosidase enzyme for the manufacture of a medicament for the treatment of glycolipid storage diseases | |
| JP4633939B2 (ja) | 治療におけるグルコシルセラミド合成阻害剤と糖脂質分解酵素の組み合わせ | |
| JP4564108B2 (ja) | デオキシノジリマイシン誘導体及び該誘導体のグルコシルセラミダーゼ阻害剤としての用途 | |
| ES2317029T3 (es) | Prevencion y tratamiento de la perdida osea inducida por inflamacion y/o mediada inmunologicamente. | |
| JP6244497B1 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| US20100093797A1 (en) | Methods For Treatment Of Cognitive And Menopausal Disorders With D-Threo Methylphenidate | |
| EP1276480B1 (en) | Levobupivacaine pharmaceutical compositions formulated on its free base form or its pharmaceutical acceptable salts and their use | |
| CN101184495B (zh) | 用于预防或降低患者中的不良作用的方法、组合物和制剂 | |
| AU2002318302A1 (en) | Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate | |
| WO2019204582A1 (en) | Stabilized polyunsaturated compounds and uses thereof | |
| WO2008140828A1 (en) | Inhibitors of acetyl-coa carboxylase for treatment of neuronal hypometabolism | |
| KR100969634B1 (ko) | 글루코사민 또는 글루코사민 유도체를 포함하는 아토피성피부염 치료용 조성물 및 이를 사용하여 아토피성 피부염을치료하는 방법 | |
| US20160303150A1 (en) | Deuterated trehalose formulations and uses thereof | |
| US20220362189A1 (en) | Combination therapy with acetyl-leucine and miglustat | |
| US20200237742A1 (en) | Serdexmethylphenidate Conjugates, Compositions And Methods Of Use Thereof | |
| US6469064B2 (en) | Materials and methods for the treatment of depression | |
| Brodkin | Myoglobinuria following epsilon-aminocaproic acid (EACA) therapy: case report | |
| HK40127928A (en) | Combination therapy with acetyl-leucine and miglustat for treating a lysosomal storage disease | |
| HK40114082A (zh) | 新型苯衍生物及其免疫抑制相关用途 | |
| JP2024113337A (ja) | 変形性関節症治療用医薬組成物及びキット | |
| CN108368131A (zh) | 用于治疗阿尔茨海默氏病和/或大脑淀粉样血管病的新颖化合物和方法 | |
| Matthews | Statin therapy correlates with improved outcomes following carotid endarterectomy | |
| WO1998058647A1 (en) | Acetaminophen and cisapride analgesics | |
| JP2013518814A (ja) | ＤＧＪＮＡｃのＤ−グルクロノラクトンからの合成およびα−Ｎ−アセチルガラクトサミニダーゼを阻害するための使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061115 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20061115 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100521 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20101014 |